Chameleon Association

Chameleon Biosciences is a clinical-stage biotechnology company developing a proprietary platform to improve the safety and efficacy of gene therapies. The company's core technology, known as EVADE (Extra-Vascular Adeno-associated virus Delivery), involves cloaking adeno-associated virus (AAV) vectors with a lipid membrane to shield them from the patient's immune system. This approach is designed to reduce inflammatory responses and allow for lower dosing and potential redosing of gene therapies, addressing major limitations of current AAV-based treatments. Chameleon's lead program is focused on developing a more effective gene therapy for Hemophilia B.